Aurinia Pharmaceuticals Inc

Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation inducing ligand (APRIL) for the potential treatment of autoimmune diseases. Community guidelines: 1. By posting to our social media channels, or otherwise responding or commenting on our posts, you are agreeing to abide by these guidelines, which apply in addition to any terms and conditions or other notices or disclaimers that we may apply, or that may be applied by the host of the social media platform itself. Unless posts are from an official Aurinia social media handle, none of the posts or comments are posts made by us, but from members of the public. We take no responsibility for comments or posts made by third parties on our channels, and the content of those comments or posts (including any opinions or statements) may not reflect our views, and are the responsibility of the individual posting them. We may discuss medical and health-related topics on our social media feeds. The content we post, and any associated content shared by other users, should not be taken as medical advice. We ask that you refrain from soliciting or posting medical advice on this feed. For advice and information related to your health, please seek advice from your doctor or other healthcare professional. Aurinia reserves the right to remove any content or comments that violate these guidelines or are otherwise deemed inappropriate. We may block or ban users who repeatedly violate these guidelines or engage in disruptive behavior. To learn more, visit: US-NA-2300266 08/23